JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the 11 Dirt Cheap Stocks to Buy According to Analysts. On October 3, JPMorgan increased its price target on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from $23 to $26 while keeping an Overweight rating.

This decision comes as part of the firm’s preview for Teva Pharmaceutical Industries Ltd.’s (NYSE:TEVA) Q3 earnings. JPMorgan expects to see no surprises.

JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)

Previously, on September 24, UBS had also increased its price target on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from $23 to $26 while keeping a Buy rating.

UBS raised its sales forecast for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) for 2030 from $6.3 billion to $6.6 billion. This includes potential revenue from the company’s Dual-Action Asthma Rescue Inhaler (ICS/SABA), expected to start in 2028. UBS expects this product to reach adjusted peak sales of $700 million in 2032.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company that focuses on innovative biopharmaceuticals and its leading generics business.

While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best American Semiconductor Stocks to Invest In and 12 Best Fintech Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.